You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Risperidone for delirium: where do we stand?
  1. Mayra Q Bocatto,
  2. Pedro Shiozawa,
  3. Alisson Paulino Trevizol,
  4. Quirino Cordeiro
  1. Clinical Neuromodulation Laboratory, Santa Casa School of Medicine, São Paulo, Brazil
  1. Correspondence to Professor Pedro Shiozawa. Department of Psychiatry, Santa Casa Medical School, Rua Major Maragliano, 241, Vila Mariana, São Paulo 01221-020, Brazil; pedroshiozawa{at}gmail.com.br

https://doi.org/10.1136/ejhpharm-2015-000874

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Second-generation antipsychotics, such as risperidone, olanzapine and quetiapine, have been studied in delirium treatment due to decreased risk of extrapyramidal symptoms.1 Our primary aim was to assess the efficacy of risperidone for the treatment of delirium. Our secondary aim was to evaluate the side effects occurrence frequency in comparison with other atypical antipsychotics and with haloperidol.

    A systematic review according to the recommendations of the Cochrane group was conducted, and the present report follows PRISMA guidelines.2 Two authors (PS and …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.